Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-01-11 Investor Presentation
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Shareholder Letter: 'Time to reveal Pharnext true value'
Investor Presentation Classification · 1% confidence The document is explicitly titled and structured as a "Shareholder Letter" from the new Chairman and CEO, Hugo Brugière, dated January 11th, 2023. This letter introduces the new leadership, outlines strategic priorities (clinical study completion, operational optimization, asset valuation), and discusses future milestones (Phase III results, potential M&A activity). This format—a direct communication from management to shareholders regarding strategy, performance outlook, and governance changes—fits best under the general category of investor communication or management reporting. While it discusses clinical trials (which might suggest an IR or MDA), its primary function is a direct address/update to owners. It is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). It is a specific type of communication to investors, which aligns closely with the intent of an Investor Presentation (IP) or a detailed Management Report (MDA), but given the direct, personal letter format addressing strategy and leadership change, it functions as a high-level management update. However, since it is a direct letter to shareholders detailing strategy and outlook, it is most appropriately classified as an Investor Presentation (IP) or Management Discussion & Analysis (MDA). Given the focus on strategy, outlook, and leadership introduction, MDA (Management Reports) is a strong fit, as is IP (Investor Presentation). Since it is a letter format rather than a slide deck, MDA is slightly more appropriate for a detailed narrative update from management. If 'LTR' (Legal Proceedings Report) or 'DEF 14A' (Remuneration) were not relevant, and it's not a formal financial report, MDA captures the essence of management's narrative review and outlook.
2023-01-11 English
Pharnext engage des discussions avec le bureau d'analyse financière Edison Investment Research en vue d'une actualisation de la valorisation de ses actifs
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the company has engaged a financial research firm (Edison Investment Research) to update its asset valuation and research note. It does not contain financial statements, audit results, or regulatory filings, but rather serves as a corporate announcement regarding future research coverage. As it does not fit into specific categories like Earnings Release or Investor Presentation, it falls under the general regulatory/corporate announcement category. Q1 2023
2023-01-05 French
Pharnext in discussions with investment research firm Edison to update valuation of assets
Regulatory Filings Classification · 1% confidence The document is a press release dated January 5th, 2023, announcing that Pharnext is in discussions with Edison Investment Research to update the valuation of its assets. It explicitly mentions that Edison is planning to publish an updated financial analysis note by the end of Q1 2023. This document is an announcement about future research/analysis, not the research itself, nor is it a formal regulatory filing like a 10-K or an Earnings Release (ER). It is a general corporate update regarding investor relations and potential strategic transactions (takeover context). Since it is an announcement regarding future investor materials and general corporate news that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially Investor Presentation (IP) if the context was more about presenting strategy, but here it is about an external valuation update. Given the nature of updating investors on external research and strategic positioning, RNS serves as the best general regulatory announcement fallback, although it is closely related to investor communication.
2023-01-05 English
Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new executive, Scott Johnson, as VP, Head of Quality, and details the composition of the Senior Leadership Team (SLT). This type of announcement, focusing on changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT).
2023-01-04 English
Pharnext renforce son équipe de direction avec la nomination de Scott Johnson au poste de VP, Directeur de la Qualité
Board/Management Information Classification · 1% confidence The document is a press release from Pharnext announcing the appointment of Scott Johnson as VP, Head of Quality. The content focuses entirely on personnel changes within the senior management team, detailing the new appointee's background and listing other key management members. This directly aligns with the definition of 'Board/Management Information' (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as the primary subject is executive staffing.
2023-01-04 French
Pharnext strengthens its ties with Néovacs to secure the next steps in its development
Board/Management Information Classification · 1% confidence The document is a press release dated December 28th, 2022, announcing significant corporate actions: an increase in funding commitment from Néovacs, the appointment of a new Chairman and CEO (Hugo Brugière), and the creation of a committee to search for a strategic industrial partner. These announcements relate to corporate governance changes (CEO appointment) and financing/strategic direction updates. It is not a formal regulatory filing like a 10-K or an IR, nor is it a transcript (CT) or a simple dividend notice (DIV). The key elements point towards management changes and strategic financing/partnership discussions. Since it involves the appointment of senior management (Chairman and CEO), the 'Board/Management Information' (MANG) category is the most appropriate fit, as it directly addresses changes in senior management.
2022-12-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.